DCP-001 becomes vididencel

Stockholm, Sweden

Following a transformative year with proof-of-concept data presented at the ASH 2022 Annual Meeting last December, the progress of our lead product candidate DCP-001 is now being reflected in the INN name “vididencel” selected by the World Health Organization’s International Nonproprietary Names Expert Committee and we will increasingly use it in all our materials.

Meanwhile, the ADVANCE II study will continue to generate survival data in the long-term follow up period while Mendus is preparing next steps for continued development of the vididencel program

Keep reading

Immunicum AB (publ) Announces Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer to Evaluate Ilixadencel in Combination with Avelumab in Multi-Indication Phase Ib/II Study